Streetbeat News

Regulatory

COP

MRO

Marathon Oil has received demand letters and complaints from stockholders concerning its deal with ConocoPhillips. In response, Marathon Oil has voluntarily issued additional disclosures while denying all allegations.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:33 pm

LQDA

MREO

SERV

SHAK

YXT

Several stocks experienced declines in Monday's pre-market session. Liquidia Corporation saw a significant drop after FDA's tentative approval of YUTREPIA. Shake Shack was downgraded by Piper Sandler, contributing to its decline. Other stocks like YXT.COM, Mereo BioPharma, and Serve Robotics also faced losses.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 12:27 pm

EBS

GOVX

VRAX

Shares of vaccine and mpox-related stocks are trading higher following the WHO's declaration of the virus as a global health emergency last week.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:16 pm

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:04 pm

AKTX

Akari Therapeutics received positive Pre-IND feedback from the FDA for its eye disease treatment, PAS-nomacopan. This feedback clarifies the company's preclinical plans, drug manufacturing, and Phase 1 clinical strategy. The IND is expected to be submitted in 2025.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:02 pm

LQDA

Liquidia shares are trading lower after the FDA granted tentative approval for YUTREPIA inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:55 am

MIRA

MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) is nearing the submission of its Investigational New Drug (IND) application for Ketamir-2 by the end of the year. The company has strengthened its leadership with the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Significant progress has been made with Ketamir-2, a novel oral ketamine analog, which has shown a superior safety profile and efficacy in preclinical studies. Additionally, MIRA-55, a novel oral pharmaceutical marijuana analog, has demonstrated promising results and is not classified as a controlled substance by the DEA.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:35 am

GLUE

Monte Rosa Therapeutics has initiated dosing in a Phase 1 study of MRT-6160, targeting VAV1 for systemic and neurological autoimmune diseases. Initial data is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:11 am

AIOT

Powerfleet, Inc. (NASDAQ:AIOT) has received clearance from the SEC regarding its recent merger with MiX Telematics Ltd. This allows Powerfleet to file its Transition Report on Form 10-KT and its Quarterly Report on Form 10-Q. The company will report its first fiscal quarter results on August 22, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:09 am

INVE

Identiv, Inc. (NASDAQ:INVE) has received approval from the Committee on Foreign Investment in the United States (CFIUS) to sell its Physical Security Business to Vitaprotech for $145 million. The transaction is expected to close within 30 days, significantly strengthening Identiv's financial position and allowing it to focus on its IoT solutions business.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:07 am